Announcements Trials

Browse Landscape

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neoplasms 6 Neoplasm Metastasis 5 Melanoma 5 Carcinoma, Non-Small-Cell Lung 5 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Neoplasms by Site 3 Hereditary Sensory and Autonomic Neuropathies 3 Endometrial Neoplasms 3 Breast Diseases 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neuroblastoma 2 Multiple Endocrine Neoplasia Type 1 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Teratoma 1 Stomach Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumors 1 Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteitis Deformans 1 Neoplasms, Germ Cell and Embryonal 1

Interventions

ribociclib 1 Drug Therapy, Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HR+HER2- Advanced Breast Cancer × ribociclib × Clear all

NCT06148506 2025-12-05

ValerEE

Novartis

Active not recruiting

HR+HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡